Autor
WE. Evans / MV. Relling
La serie Pharmacotherapy revisited de la Fundación Dr. Antonio Esteve, ha reunido en su quinto volumen los principales artículos, en edición facsímil, que se han publicado entre 1980 y 2000 sobre farmacodinámica y farmacogenética del cáncer. Editado por William E. Evans y Mary V. Relling, del Departamento de Ciencias Farmacéuticas del Hospital St. Jude Children de Memphis, Estados Unidos, esta recopilación pretende reunir dentro de una misma publicación algunos de los avances más importantes que se han realizado en el campo de las investigaciones contra el cáncer y del tratamiento de los pacientes.
| Documento entero | ||
| Documento entero | WE. Evans / MV. Relling | [wpdm type=”btn3″] |
| Capítulos | ||
| Chapters | Acknowledgements | [wpdm id=27 type=”btn”] |
| Introduction | WE. Evans / MV. Relling | [wpdm id=29 type=”btn”] |
| Index | [wpdm id=28 type=”btn”] | |
| 1. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function | MJ. Egorin / DA. Van Echo / SJ. Tipping / EA. Olman / MY. Whitacre / BW. Thompson / J. Aisner | [wpdm type=”btn3″] |
| 2. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect | WE. Evans / WR. Crom / M. Abromowitch / R. Dodge / AT. Look / WP. Bowman / SL. George / C-H. Pui | [wpdm type=”btn3″] |
| 3. Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial | JH. Rodman / M. Abromowitch / JA. Sinkule / FA. Hayes / GK. Rivera / WE. Evans | [wpdm type=”btn3″] |
| 4. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation | GC. Yee / SG. Self / TR. McGuire / J. Carlin / JE. Sanders / HJ. Deeg | [wpdm type=”btn3″] |
| 5. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity | RB. Diasio / TL. Beavers / JT. Carpenter | [wpdm type=”btn3″] |
| 6. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function | AH. Calvert / DR. Newell / LA. Gumbrell / S. O\’Reilly / M. Burnell / FE. Boxall / ZH. Siddik / IR. Judson / ME. Gore / E. Wiltshaw | [wpdm type=”btn3″] |
| 7. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation | LB. Grochow / RJ. Jones / RB. Brundrett / HG. Braine / T-L. Chen / R. Saral / GW. Santos / OM. Colvin | [wpdm type=”btn3″] |
| 8. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia | L. Lennard / JS. Lilleyman / J. Van Loon / RM. Weinshilboum | [wpdm type=”btn3″] |
| 9. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia | WE. Evans / M. Horner / YQ. Chu / D. Kalwinsky / WM. Roberts | [wpdm type=”btn3″] |
| 10. Relation of systemic exposure to unbound etoposide and hematologic toxicity | CF. Stewart / SG. Arbuck / RA. Fleming / WE. Evans | [wpdm type=”btn3″] |
| 11. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer | DI. Jodrell / MJ. Egorin / RM. Canetta / P. Langenberg / EP. Goldbloom / JN. Burroughs / JL. Goodlow / S. Tan / E. Wiltshaw | [wpdm type=”btn3″] |
| 12. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion | J-M. Extra / F. Rousseau / R. Bruno / M. Clavel / N. Le Bail / M. Marty | [wpdm type=”btn3″] |
| 13. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy | V. Gandhi / E. Estey / MJ. Keating / W. Plunkett | [wpdm type=”btn3″] |
| 14. Relationship between fluorouracil systemic exposure and tumor response and patient survival | G. Milano / MC. Etienne / N. Renée / A. Thyss / M. Schneider / A. Ramaioli / F. Demard | [wpdm type=”btn3″] |
| 15. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia | TW. Synold / MV. Relling / JM. Boyett / GK. Rivera / JT. Sandlund / H. Mahmoud / WM. Crist / C-H. Pui / WE. Evans | [wpdm type=”btn3″] |
| 16. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors | DS. Sonnichsen / CA. Hurwitz / CB. Pratt / JJ. Shuster / MV. Relling | [wpdm type=”btn3″] |
| 17. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans | L. Gianni / CM. Kearns / A. Giani / G. Capri / L. Viganó / A. Locatelli / G. Bonadonna / MJ. Egorin | [wpdm type=”btn3″] |
| 18. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance | CR. Yates / EY. Krynetski / T. Loennechen / MY. Fessing / H-L. Tai / C-H. Pui / MV. Relling / WE. Evans | [wpdm type=”btn3″] |
| 19. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation | JT. Slattery / RA. Clift / CD. Buckner / J. Radich / B. Storer / WI. Bensinger et al. | [wpdm type=”btn3″] |
| 20. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia | WE. Evans / MV. Relling / JH. Rodman / WR. Crom / JM. Boyett / C-H. Pui | [wpdm type=”btn3″] |
| 21. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes | L. Iyer / CD. King / PF. Whitington / MD. Green / SK. Roy / TR. Tephly / BL. Coffman / MJ. Ratain | [wpdm type=”btn3″] |
| 22. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus | MV. Relling / ML. Hancock / GK. Rivera / JT. Sandlund / RC. Ribeiro / EY. Krynetski / C-H. Pui / WE. Evans | [wpdm type=”btn3″] |
